Navigation Links
Islet Sciences Announces Strategic Alliance with Spring Point Project
Date:8/7/2012

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has signed a strategic alliance with Spring Point Project.

Spring Point Project's team has unique experience under the current Good Manufacturing Practices (cGMP) required by U.S. Food and Drug Administration regulations. Thanks to a substantial donation from the Diabetes Resource and Wellness Foundation, Spring Point Project's 21,000-square-foot facility – the Diabetes Research and Wellness Islet Resource Facility – was opened in February 2007.

"This partnership is an important piece in our strategy to initiate our Islet transplantation trial using encapsulated Islet cells," stated John Steel, Chairman and CEO of Islet Sciences. "We are pleased to announce this collaboration as we continue to add important Diabetes focused partners to our program."

"Our entire Science team is excited to work with Spring Point because of their commitment and vision for persons with Insulin dependent Diabetes," stated Dr. Jonathan Lakey, Chief Scientific Officer of Islet Sciences. "We are pleased to announce this strategic alliance with such a credible partner that can provide this unique capability."

"We are delighted to partner with Islet Sciences as they prepare for their upcoming clinical trials," stated Tom Spizzo, Executive Director of Spring Point Project. "Our team and facility have the exceptional capabilities needed to support such a trial as Islet Sciences implements their novel scientific approach."

About Spring Point Project

Spring Point Project, headquartered in Minneapolis, MN, is working to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes. Spring Point Project works to provide the suitable pig islet source academia and the biotechnology industry required to move toward a cure for diabetes. For more information on Spring Point Project, visit www.SpringPointProject.org.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Group
(646) 863-6893
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
2. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):